Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOCATS: Neoadjuvant Triplet in Advanced Ovarian Cancer
NCT06650709Phase 2Not yet recruiting
- Sponsor
- BC Cancer
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of olaparib, durvalumab, bevacizumab in ovarian cancer, sponsored by BC Cancer. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
olaparibdurvalumabbevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06650709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650709.